CALCIMEDICA

The CalciMedica team is comprised of scientists, physicians, drug development experts and entrepreneurs dedicated to the development of CRAC channel inhibitors for acute and chronic inflammatory conditions... CalciMedica, Inc., is focused on further developing Auxora™, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-induced pancreatic toxicity (AIPT), acute kidney injury (AKI), and acute respiratory distress syndrome (ARDS), for which there are no currently approved therapies... Leading the Way in CRAC Channel Inhibition: We are developing a new class of therapies that target the inhibition of CRAC channels and are designed to modulate the immune response and protect against tissue cell injury.

Also known as: CalciMedica Inc.

Primary location: La Jolla United States